Tirzepatide as Compared with Semaglutide for the Treatment of ObesityLouis J. Aronne, Julia P. Dunn, Carel W. le Roux et al.|New England Journal of Medicine|2025Cited by 411
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 InhibitorsBeverly L. Falcón, Donald M. McDonald|Cancer Research|2011Cited by 91
Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapyCaitlin D. Lowery, Beverly L. Falcón|Oncotarget|2019Cited by 18